IHT for Mild Cognitive Impairment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55-79
SponsorUniversity of North Texas Health Science Center
About this trial
This phase I clinical trial will examine the safety and efficacy of intermittent hypoxia training (IHT) for up to 12 weeks to treat subjects with mild cognitive impairment (MCI).
Eligibility criteria
Qualifiers
Adult men and women ages 55 to 79 years old who have been diagnosed with MCI.
Must be willing to be assigned to either group: treatment or sham-treatment control.
Able to pay multiple visits to the lab for the proposed assessments.
Able to breathe moderately hypoxic air via an air-cushioned, disposable facemask.
Disqualifiers
Unwilling to sign a written consent to participate in this double-blinded placebo-controlled phase I trial.
Diagnosed with AD-dementia or have impaired independent daily functioning; with MMSE <20 and/or CDR ≥1.
Unable to visit the lab independently.
Claustrophobic to facemask and hyper-reactive to hypoxia exposure.
Trial design
Treatments tested in this trial
- IHT Treatment
- Sham-IHT Control
Treatment groups
66 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of North Texas Health Science Center
Lead sponsor
University of Texas Southwestern Medical Center
Collaborator
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov